AVEO Oncology, EUSA Pharma announce updated interim results from phase II portion of the TiNivo study in renal cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AVEO Oncology and EUSA Pharma announced the presentation of updated interim results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib (Fotivda) in combination with intravenous nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of advanced or metastatic renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 
Silverstein during his surgical oncology fellowship, c. 1972This month on the Cancer History Project Podcast, Melvin J. Silverstein, Medical Director of Hoag Breast Center and the Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery at USC, sat down with Stacy Wentworth, radiation oncologist and medical historian, to reflect on his career—and founding the first free-standing breast center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login